BR112018010160A2 - inibidor da c1 esterase humana recombinante e usos do mesmo - Google Patents
inibidor da c1 esterase humana recombinante e usos do mesmoInfo
- Publication number
- BR112018010160A2 BR112018010160A2 BR112018010160A BR112018010160A BR112018010160A2 BR 112018010160 A2 BR112018010160 A2 BR 112018010160A2 BR 112018010160 A BR112018010160 A BR 112018010160A BR 112018010160 A BR112018010160 A BR 112018010160A BR 112018010160 A2 BR112018010160 A2 BR 112018010160A2
- Authority
- BR
- Brazil
- Prior art keywords
- esterase inhibitor
- recombinant human
- complement
- methods
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
Abstract
a presente invenção fornece, dentre outras coisas, métodos e composições para o tratamento de doenças mediadas pelo complemento. em algumas modalidades, são fornecidas proteínas inibidoras da c1 esterase humana recombinantes tendo meia-vidas semelhantes ou mais longas que o inibidor da c1 esterase humana derivada do plasma nativo, e métodos de produção das mesmas. em algumas modalidades, a invenção fornece um método para a administração de uma quantidade eficaz de uma proteína inibidora da c1 esterase humana recombinante a um indivíduo que sofre ou que esteja susceptível a uma doença mediada pelo complemento, de modo que pelo menos um sintoma ou característica da referida doença mediada pelo complemento seja evitado e/ou reduzido em intensidade, gravidade, ou frequência.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562257711P | 2015-11-19 | 2015-11-19 | |
PCT/US2016/062906 WO2017087882A1 (en) | 2015-11-19 | 2016-11-18 | Recombinant human c1 esterase inhibitor and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018010160A2 true BR112018010160A2 (pt) | 2018-11-21 |
BR112018010160A8 BR112018010160A8 (pt) | 2019-02-26 |
Family
ID=57543175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018010160A BR112018010160A8 (pt) | 2015-11-19 | 2016-11-18 | inibidor da c1 esterase humana recombinante e usos do mesmo |
Country Status (9)
Country | Link |
---|---|
US (1) | US20180334493A1 (pt) |
EP (1) | EP3377093B1 (pt) |
JP (3) | JP7189767B2 (pt) |
CN (1) | CN108463243B (pt) |
BR (1) | BR112018010160A8 (pt) |
CA (1) | CA3005906A1 (pt) |
ES (1) | ES2927271T3 (pt) |
MA (1) | MA43270A (pt) |
WO (1) | WO2017087882A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
CN112639109A (zh) | 2018-08-24 | 2021-04-09 | Csl贝林基因治疗股份有限公司 | 无血清培养基中的载体生产 |
WO2020079108A1 (en) * | 2018-10-17 | 2020-04-23 | Csl Behring Gmbh | Process for purifying c1-inh |
SE1930321A1 (en) * | 2019-10-08 | 2021-04-09 | Veronique Chotteau | A method to feed component in perfusion culture |
CN115176022A (zh) * | 2019-10-23 | 2022-10-11 | 夏尔人类遗传性治疗公司 | 用于遗传性血管性水肿的基于腺相关病毒载体的基因疗法 |
CN111087475B (zh) * | 2019-12-25 | 2022-07-08 | 东莞市东阳光生物药研发有限公司 | Fgf21融合蛋白及抑制其降解的方法 |
RU2769201C2 (ru) * | 2020-06-23 | 2022-03-29 | Акционерное общество "ГЕНЕРИУМ" | Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения |
JP2023538881A (ja) * | 2020-08-14 | 2023-09-12 | ブリストル-マイヤーズ スクイブ カンパニー | タンパク質の製造方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5622930A (en) * | 1989-10-27 | 1997-04-22 | Clb | C1 inhibitor muteins and uses thereof |
US5096816A (en) | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
FR2672895B1 (fr) | 1991-02-15 | 1995-05-12 | Transgene Sa | Procede de purification d'une proteine fortement glycosylee. |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
JP3543106B2 (ja) * | 1999-07-21 | 2004-07-14 | 大阪大学長 | 膜結合型c1インアクチベーター |
EP1252184B1 (en) * | 2000-01-31 | 2008-01-02 | Pharming Intellectual Property B.V. | Human c1 inhibitor produced in the milk of transgenic mammals |
CA2492267C (en) | 2002-07-15 | 2013-09-10 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
US8524477B2 (en) | 2002-10-29 | 2013-09-03 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
US7384754B2 (en) | 2003-10-31 | 2008-06-10 | Agilent Technologies, Inc. | Enrichment and tagging of glycosylated proteins |
GB0507123D0 (en) | 2005-04-08 | 2005-05-11 | Isis Innovation | Method |
EP3026109B1 (en) | 2005-12-08 | 2022-03-09 | Amgen Inc. | Improved production of glycoproteins using manganese |
KR101508668B1 (ko) * | 2005-12-21 | 2015-04-06 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | 허혈-재관류 손상의 예방을 위한 c1 억제제의 용도 |
WO2008029281A2 (en) | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
IL182956A0 (en) | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
JP2011500032A (ja) | 2007-10-12 | 2011-01-06 | シグマ−アルドリッチ・カンパニー | 糖タンパク質のシアリル化を改善するための組成物および方法 |
KR101556514B1 (ko) | 2008-02-19 | 2015-10-02 | 바이오콘 리미티드 | 효모에서 발현된 정제된 이형 인슐린을 수득하는 방법 |
WO2009143493A2 (en) * | 2008-05-22 | 2009-11-26 | Attagene Inc. | MODULATORS OF TNFα-DEPENDENT SIGNALING PATHWAYS AND USES THEREOF |
EP2166085A1 (en) | 2008-07-16 | 2010-03-24 | Suomen Punainen Risti Veripalvelu | Divalent modified cells |
WO2010099394A1 (en) | 2009-02-26 | 2010-09-02 | Battelle Energy Alliance, Llc | Alteration and modulation of protein activity by varying post-translational modification |
US20130085111A1 (en) * | 2010-03-18 | 2013-04-04 | Thrombolytic Science, Llc | Production of human c1 inhibitor in human cells |
ES2563763T3 (es) | 2011-02-10 | 2016-03-16 | F. Hoffmann-La Roche Ag | Método para la purificación de un glicano y/o un glicoconjugado mediante cromatografía usando un algodón que comprende la fase estacionaria |
CA2840951A1 (en) | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Methods for purifying fc-fusion protein |
WO2013093760A2 (en) | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
DK2793935T3 (en) * | 2011-12-22 | 2016-09-05 | Csl Behring Gmbh | Use of C1 inhibitor in the treatment of secondary edema in the central nervous system. |
JP2015512370A (ja) * | 2012-03-16 | 2015-04-27 | ベルローズ ファーマ,インコーポレーテッド | C1−阻害剤のポリマーコンジュゲート |
AU2014224599B2 (en) * | 2013-03-08 | 2018-11-08 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
PT2968434T (pt) * | 2013-03-15 | 2017-09-18 | Shire Viropharma Inc | Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase |
AU2015222756A1 (en) * | 2014-02-28 | 2016-08-18 | Santarus, Inc. | Treatment of hereditary angioedema with C1 inhibitor |
IL275497B (en) * | 2014-03-20 | 2022-09-01 | Bristol Myers Squibb Co | Serum proteins with type iii fibronectin binding domains |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
WO2016081889A1 (en) * | 2014-11-21 | 2016-05-26 | Kurt Baekgaard Osther | Recombinant c1 esterase inhibitor and use thereof |
EP3042952A1 (en) * | 2015-01-07 | 2016-07-13 | CEVEC Pharmaceuticals GmbH | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same |
-
2016
- 2016-11-18 WO PCT/US2016/062906 patent/WO2017087882A1/en active Application Filing
- 2016-11-18 US US15/777,547 patent/US20180334493A1/en active Pending
- 2016-11-18 ES ES16810158T patent/ES2927271T3/es active Active
- 2016-11-18 MA MA043270A patent/MA43270A/fr unknown
- 2016-11-18 JP JP2018526218A patent/JP7189767B2/ja active Active
- 2016-11-18 BR BR112018010160A patent/BR112018010160A8/pt active Search and Examination
- 2016-11-18 CN CN201680078763.5A patent/CN108463243B/zh active Active
- 2016-11-18 EP EP16810158.2A patent/EP3377093B1/en active Active
- 2016-11-18 CA CA3005906A patent/CA3005906A1/en active Pending
-
2021
- 2021-06-25 JP JP2021105576A patent/JP2021155438A/ja active Pending
-
2023
- 2023-04-21 JP JP2023070030A patent/JP2023083499A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN108463243B (zh) | 2022-06-14 |
JP2023083499A (ja) | 2023-06-15 |
CN108463243A (zh) | 2018-08-28 |
MA43270A (fr) | 2021-06-02 |
ES2927271T3 (es) | 2022-11-03 |
US20180334493A1 (en) | 2018-11-22 |
WO2017087882A1 (en) | 2017-05-26 |
BR112018010160A8 (pt) | 2019-02-26 |
JP7189767B2 (ja) | 2022-12-14 |
CA3005906A1 (en) | 2017-05-26 |
JP2021155438A (ja) | 2021-10-07 |
JP2018538270A (ja) | 2018-12-27 |
EP3377093B1 (en) | 2022-07-13 |
EP3377093A1 (en) | 2018-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018010160A8 (pt) | inibidor da c1 esterase humana recombinante e usos do mesmo | |
BR112017008962A2 (pt) | proteínas de fusão inibidoras de c1 esterase e usos das mesmas | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
EA201792501A1 (ru) | Вакцины для лечения и профилактики рака | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
CL2018002826A1 (es) | Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
BR112016024850A2 (pt) | composições e métodos para modulação da expressão 3 semelhante a antiopoietina | |
BR112016028520A2 (pt) | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina | |
BR112018014288A2 (pt) | métodos e composições para o tratamento de doença neurológica | |
EA201990257A1 (ru) | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением | |
BR112018067747A2 (pt) | proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne | |
BR112017012682A2 (pt) | processo para aperfeiçoamento de porções de músculo e produtos | |
BR112015021483A2 (pt) | arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer | |
BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
CL2018002767A1 (es) | Método para seleccionar proteínas recombinantes ricas en m6p | |
BR112016011489A2 (pt) | composição nutricional pediátrica com peptídeos do leite para crescimento e desenvolvimento saudável | |
CO2020000369A2 (es) | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos | |
BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
BR112017013696A2 (pt) | peptídeos e seu uso no tratamento de pele | |
BR112018003780A2 (pt) | composições que compreendem um composto de urolitina | |
AR095334A1 (es) | Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable | |
BR112019022912A2 (pt) | Métodos e composições para tratar doenças oculares alérgicas | |
BR112017008805A2 (pt) | tratamento de córnea usando laminina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |